Market Research Logo

US Market Report for Liquid Embolics 2017 - MedCore

US Market Report for Liquid Embolics 2017 - MedCore

There will be flat growth in the liquid embolics market over the forecast period. The, “A Randomized trial of Unruptured Brain Arteriovenous malformations” (ARUBA) trial compared interventional and conservative treatment of arteriovenous malformations in the brain. Conservative treatment consisted of a regimen of medication while the intervention arm included embolization. The trial was halted in 2013 due to excessive morbidity associated with the interventional arm. This outcome slowed growth in terms of unit sales in liquid embolics. Innovation in microcatheters to reduce complications in liquid embolic delivery may slightly increase unit sales. Overall growth in units sold will be flat. The total U.S. liquid embolic market includes TRUFILL n-BCA® from Codman & Shurtleff, Inc and Onyx® from Medtronic. Codman has been on the market for longer and tends to have slightly higher pricing however the ASP will be relatively flat over the projected period.

Liquid embolics currently on the market include N-butyl cyanoacrylate (NBCA) (TRUFILL®) and an ethylene-vinyl alcohol copolymer (Onyx®). These agents are injected through microcatheters and act like glue in abnormal blood vessels. When they contact blood they solidify and obstruct the vessel lumen therefore blocking the flow of blood through malformed blood vessels and reducing the risk of rupture. The surgeon performing the procedure must flush the catheter before and after injecting the NBCA to prevent the liquid agent from sticking to the catheter. Thus this procedure requires a highly skilled physician. This is often done prior to the removal of these vessels in order to simplify the surgical procedure.


EXECUTIVE SUMMARY
U.S. NEUROMODULATION, NEUROVASCULAR, NEUROSURGICAL AND MONITORING DEVICE MARKET OVERVIEW
COMPETITIVE ANALYSIS
MARKET TRENDS
MARKET DEVELOPMENTS
PROCEDURE NUMBERS
PROCEDURE CODES INVESTIGATED
MARKETS INCLUDED
KEY REPORT UPDATES
VERSION HISTORY
RESEARCH METHODOLOGY
1.1 RESEARCH SCOPE
1.2 IDATA’S 9-STEP METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
DISEASE OVERVIEW
2.1 BASIC ANATOMY
2.2 DISEASE PATHOLOGY AND DISORDERS
2.2.1 Introduction
2.2.2 General Diagnostics and Neurosurgery
2.2.3 Tumor and Brain Cancer
2.2.4 Brain Arteriovenous Malformations
2.2.5 Ischemic Stroke
2.2.6 Brain Aneurysm
2.2.7 Disorders Related to Cerebrospinal Fluids and Intracranial Pressure
2.2.7.1 Hydrocephalus and Intracranial Pressure Disorder
2.2.7.2 Cerebral Edema
2.2.8 Indication for Neuromodulation
2.2.9 Traumatic brain injury
PRODUCT ASSESSMENT
3.1 PRODUCT PORTFOLIOS
3.1.1 Liquid Embolics
3.1.1.1 Introduction
3.1.1.2 Product Matrix for Liquid Embolics Market: Core Companies
3.2 REGULATORY ISSUES AND RECALLS
3.2.1 Liquid Embolics
3.3 CLINICAL TRIALS
3.3.1 Liquid Embolic
LIQUID EMBOLIC MARKET
4.1 INTRODUCTION
4.2 MARKET ANALYSIS AND FORECAST
4.3 DRIVERS AND LIMITERS
4.3.1 Market Drivers
4.3.2 Market Limiters
4.4 COMPETITIVE MARKET SHARE ANALYSIS
ABBREVIATIONS
APPENDIX: COMPANY PRESS RELEASES
List of Charts
Chart 1 1: Neurological Device Market by Segment, U.S., 2013 – 2023
Chart 1 2: Neurological Device Market Overview, U.S., 2016 & 2023
Chart 4 1: Liquid Embolic Market, U.S., 2013 – 2023
Chart 4 2: Leading Competitors, Liquid Embolic Market, U.S., 2016
List of Figures
Figure 1 1: Neurological Device Market Share Ranking by Segment, U.S., 2016 (1 of 3)
Figure 1 2: Neurological Device Market Share Ranking by Segment, U.S., 2016 (2 of 3)
Figure 1 3: Neurological Device Market Share Ranking by Segment, U.S., 2016 (3 of 3)
Figure 1 4: Companies Researched in this Report, U.S., 2016
Figure 1 5: Factors Impacting the Neurological Device Market by Segment, U.S. (1 of 3)
Figure 1 6: Factors Impacting the Neurological Device Market by Segment, U.S. (2 of 3)
Figure 1 7: Factors Impacting the Neurological Device Market by Segment, U.S. (3 of 3)
Figure 1 8: Recent Events in the Neurological Device Market, U.S., 2014 – 2016
Figure 1 9: Neurological Device Markets Covered, U.S., 2016
Figure 1 10: Procedural Codes Investigated, U.S., 2016 (1 of 2)
Figure 1 11: Procedural Codes Investigated, U.S., 2016 (2 of 2)
Figure 1 12: Neurological Device Markets Covered, U.S., 2016 (1 of 2)
Figure 1 13: Neurological Device Markets Covered, U.S., 2016 (2 of 2)
Figure 1 14: Key Report Updates
Figure 1 15: Version History
Figure 2 1: Neurology Disease Overview
Figure 2 2: Brain/Other Nervous System Cancer Statistics by Type and Gender, U.S., 2016
Figure 3 1: Class 1 Device Recall: nButyl Cyanoacrylate (nBCA) Liquid Embolic System (TRUFILL, Codman)
Figure 3 2: Liquid Embolic: Apollo™ Onyx™ Delivery Micro Catheter Post Market Safety Study
Figure 3 3: Liquid Embolic: Safety of Apollo Micro Catheter in Pediatric Patients
Figure 3 4: Liquid Embolic: TRUfill®'s Line in Intracranial aNeurysm Embolisation (TRULINE)
Figure 4 1: Liquid Embolic Market, U.S., 2013 – 2023
Figure 4 2: Drivers and Limiters, Liquid Embolic Market, U.S., 2016
Figure 4 3: Leading Competitors, Liquid Embolic Market, U.S., 2016
Figure 6 1: Press Release Summary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report